PriceTargets.com logo

PLx Pharma - PLXP Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: NaN
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$0.00 As of 09/29/2023 01:00 AM ET
+0 (0.00%)
Get New PLx Pharma Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for PLXP and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for PLXP

Analyst Price Target is $0.00
This price target is based on 0 analysts offering 12 month price targets for PLx Pharma in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a NaN upside from the last price of $0.00.

This chart shows the closing price for PLXP for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is N/A

The current consensus among 0 investment analysts is to n/a stock in PLx Pharma. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/27/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/25/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/25/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/24/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/22/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/20/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/20/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/19/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/15/2022JMP SecuritiesDowngradeOutperform ➝ Market PerformLow
8/15/2022OppenheimerDowngradeOutperform ➝ Market PerformLow
3/14/2022Raymond JamesLower TargetOutperform$14.00 ➝ $12.00High
12/7/2021Raymond JamesUpgradeMarket Perform ➝ Outperform$14.00High
11/1/2021JMP SecuritiesReiterated RatingBuy$21.00Low
9/21/2021BWS FinancialInitiated CoverageBuy$29.00High
8/20/2021JMP SecuritiesReiterated RatingBuy$21.00High
7/20/2021JMP SecuritiesBoost TargetOutperform$12.00 ➝ $21.00High
7/20/2021OppenheimerReiterated RatingBuy$22.00High
4/9/2021OppenheimerInitiated CoverageOutperform$20.00High
3/1/2021JMP SecuritiesBoost TargetOutperform$9.00 ➝ $12.00Low
8/14/2020Raymond JamesReiterated RatingHold ➝ HoldLow
5/18/2020JMP SecuritiesInitiated CoverageOutperformMedium
(Data available from 4/19/2019 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/22/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/22/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/21/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/21/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/20/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/19/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/20/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/19/2024

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
PLx Pharma logo
PLx Pharma, Inc. is a late-stage specialty pharmaceutical company, which engages in the development and commercialization of technology platform for approved drugs. It offers PLxGuard delivery system, which uses surface acting lipids, such as phospholipids and free fatty acids, to modify the physiochemical properties of various drugs with a targeted release to select portions of the gastrointestinal (GI) tract. The company was founded by Ronald R. Zimmerman on November 12, 2002 and is headquartered in Sparta, NJ.
Read More

Today's Range

Now: N/A

50 Day Range

MA: N/A

52 Week Range

Now: N/A

Volume

3,000 shs

Average Volume

12,962,128 shs

Market Capitalization

$603 thousand

P/E Ratio

N/A

Dividend Yield

N/A

Beta

3.79

Frequently Asked Questions

What sell-side analysts currently cover shares of PLx Pharma?

The following Wall Street analysts have issued stock ratings on PLx Pharma in the last twelve months:
View the latest analyst ratings for PLXP.

What is the current price target for PLx Pharma?

0 Wall Street analysts have set twelve-month price targets for PLx Pharma in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for PLx Pharma in the next year.
View the latest price targets for PLXP.

What is the current consensus analyst rating for PLx Pharma?

PLx Pharma currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for PLXP.

What other companies compete with PLx Pharma?

Other companies that are similar to PLx Pharma include Aditxt, Bellerophon Therapeutics, Allarity Therapeutics, China SXT Pharmaceuticals and Evofem Biosciences. Learn More about companies similar to PLx Pharma.

How do I contact PLx Pharma's investor relations team?

PLx Pharma's physical mailing address is 9 Fishers Lane Suite E, Sparta NJ, 07871. The biotechnology company's listed phone number is (973) 409-6541 and its investor relations email address is [email protected]. The official website for PLx Pharma is www.plxpharma.com. Learn More about contacing PLx Pharma investor relations.